Obesity drugs have displaced oncology as the largest contributor to pharma R&D returns
Published on May 4, 2026.
The obesity epidemic has led to a decrease in the number of successful treatments in the pharmaceutical industry, with GLP-1 drugs for weight loss and diabetes becoming particularly prevalent. However, this poses a significant risk for the company. The pharmaceutical industry has been criticized for focusing on the health of the patient.
Related Articles
Meet Trump's New Surgeon General Nominee: She's Pro-Life, Anti-Big Government and Opposed COVID Lockdowns
President Donald Trump is nominating radiologist Nicole Saphier for the role of Surgeon General, emphasizing her pro-life, anti-big government, and opposition to COVID Lockdowns.
Report shows health care gaps for Hispanic Arkansans
A new Commonwealth Fund report reveals significant health disparities between Hispanic Arkansas residents and their counterparts, with high rates of uninsuredness and poor quality compared to white residents.
Dakota County's street grid is the key that unlocks the suburbs
Dakota County's alphabetical street grid helps navigate large swaths of the south metro, tracing its development through alphabetical patterns like this.